IL243365B - T-cells with high stability and a method for their preparation - Google Patents

T-cells with high stability and a method for their preparation

Info

Publication number
IL243365B
IL243365B IL243365A IL24336515A IL243365B IL 243365 B IL243365 B IL 243365B IL 243365 A IL243365 A IL 243365A IL 24336515 A IL24336515 A IL 24336515A IL 243365 B IL243365 B IL 243365B
Authority
IL
Israel
Prior art keywords
stability
preparation
application
cell receptor
receptor
Prior art date
Application number
IL243365A
Other languages
English (en)
Hebrew (he)
Other versions
IL243365A0 (en
Inventor
Yi 2 Jinfeng Road Li
Original Assignee
Yi 2 Jinfeng Road Li
Guangdong Xiangxue Life Sciences Ltd
Guangznoh Xiangxue Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52141082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL243365(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yi 2 Jinfeng Road Li, Guangdong Xiangxue Life Sciences Ltd, Guangznoh Xiangxue Pharmaceutical Co Ltd filed Critical Yi 2 Jinfeng Road Li
Publication of IL243365A0 publication Critical patent/IL243365A0/en
Publication of IL243365B publication Critical patent/IL243365B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL243365A 2013-06-26 2015-12-27 T-cells with high stability and a method for their preparation IL243365B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310263384 2013-06-26
PCT/CN2014/080773 WO2014206304A1 (zh) 2013-06-26 2014-06-25 高稳定性的t细胞受体及其制法和应用

Publications (2)

Publication Number Publication Date
IL243365A0 IL243365A0 (en) 2016-03-31
IL243365B true IL243365B (en) 2020-07-30

Family

ID=52141082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243365A IL243365B (en) 2013-06-26 2015-12-27 T-cells with high stability and a method for their preparation

Country Status (12)

Country Link
US (1) US10654906B2 (de)
EP (1) EP3015477B1 (de)
JP (1) JP6549564B2 (de)
KR (1) KR101904385B1 (de)
CN (1) CN105683215B (de)
AU (2) AU2014301777B2 (de)
CA (1) CA2916960C (de)
IL (1) IL243365B (de)
MX (1) MX2016000231A (de)
NZ (1) NZ715815A (de)
RU (1) RU2645256C2 (de)
WO (1) WO2014206304A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3015477B1 (de) 2013-06-26 2021-08-18 XLifeSc, Ltd. Hochstabiler t-zell-rezeptor und herstellungsverfahren und anwendung davon
CN105637097A (zh) 2013-08-05 2016-06-01 特韦斯特生物科学公司 从头合成的基因文库
WO2016095783A1 (zh) * 2014-12-17 2016-06-23 中国科学院广州生物医药与健康研究院 识别eb病毒短肽的t细胞受体
CN105985427A (zh) * 2015-02-06 2016-10-05 广州市香雪制药股份有限公司 高亲和力ny-eso t细胞受体
GB201506642D0 (en) * 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
CN106279404A (zh) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 一种可溶且稳定的异质二聚tcr
EP3350314A4 (de) 2015-09-18 2019-02-06 Twist Bioscience Corporation Oligonukleinsäurevariantenbibliotheken variante und synthese davon
KR20180058772A (ko) 2015-09-22 2018-06-01 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
CN106432475B (zh) * 2015-10-19 2018-06-01 广东香雪精准医疗技术有限公司 高亲和力ny-eso t细胞受体
CN106336457B (zh) * 2015-10-30 2018-03-06 广东香雪精准医疗技术有限公司 识别mage‑a3抗原短肽的t细胞受体
CN106478807B (zh) * 2015-10-30 2018-06-01 广东香雪精准医疗技术有限公司 识别mage-a3的t细胞受体
CN106478808B (zh) * 2015-11-02 2018-06-01 广东香雪精准医疗技术有限公司 识别ny-eso-1抗原短肽的t细胞受体
CN106632658B (zh) * 2015-11-04 2020-10-27 广东香雪精准医疗技术有限公司 识别ny-eso-1抗原短肽的tcr
CN106519019B (zh) * 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN106478809B (zh) * 2015-11-06 2018-06-01 广东香雪精准医疗技术有限公司 识别prame抗原短肽的tcr
CN106831978B (zh) * 2015-12-04 2020-05-26 中国科学院广州生物医药与健康研究院 识别prame抗原的t细胞受体
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
CN106699874B (zh) * 2016-03-29 2018-06-05 广东香雪精准医疗技术有限公司 识别prame抗原短肽的t细胞受体
KR102212257B1 (ko) 2016-08-22 2021-02-04 트위스트 바이오사이언스 코포레이션 드 노보 합성된 핵산 라이브러리
WO2018057526A2 (en) 2016-09-21 2018-03-29 Twist Bioscience Corporation Nucleic acid based data storage
GB201617716D0 (en) * 2016-10-19 2016-11-30 Ucl Business Plc Cell
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
CN107964041B (zh) * 2016-10-20 2023-08-01 中国科学院广州生物医药与健康研究院 高稳定性和高亲和力的dmic及其制法
CN107987155A (zh) * 2016-10-27 2018-05-04 中国科学院广州生物医药与健康研究院 识别sage1抗原短肽的t细胞受体
CN108117596B (zh) 2016-11-29 2023-08-29 香雪生命科学技术(广东)有限公司 针对ny-eso的高亲和力tcr
EA201991262A1 (ru) 2016-12-16 2020-04-07 Твист Байосайенс Корпорейшн Библиотеки вариантов иммунологического синапса и их синтез
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别源自于prame抗原短肽的tcr
CN118116478A (zh) 2017-02-22 2024-05-31 特韦斯特生物科学公司 基于核酸的数据存储
CN110913865A (zh) 2017-03-15 2020-03-24 特韦斯特生物科学公司 免疫突触的变体文库及其合成
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
KR20240013290A (ko) 2017-06-12 2024-01-30 트위스트 바이오사이언스 코포레이션 심리스 핵산 어셈블리를 위한 방법
CN109251243B (zh) * 2017-07-13 2021-10-19 中国科学院广州生物医药与健康研究院 一种识别sage1抗原的t细胞受体及编码该受体的核酸
CN111278854A (zh) * 2017-09-04 2020-06-12 艾吉纳斯公司 与混合谱系白血病(mll)特异性磷酸肽结合的t细胞受体和其使用方法
KR20200047706A (ko) 2017-09-11 2020-05-07 트위스트 바이오사이언스 코포레이션 Gpcr 결합 단백질 및 이의 합성 방법
EP3697529B1 (de) 2017-10-20 2023-05-24 Twist Bioscience Corporation Beheizte nanowells für polynukleotidsynthese
CN109836490A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用
CN109837248A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
WO2019136175A1 (en) 2018-01-04 2019-07-11 Twist Bioscience Corporation Dna-based digital information storage
CN110016074B (zh) * 2018-01-08 2021-03-30 中国科学院广州生物医药与健康研究院 Mage-a3人源化t细胞受体
WO2019162043A1 (en) * 2018-02-26 2019-08-29 Medigene Immunotherapies Gmbh Nyeso tcr
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
CN110776562B (zh) * 2018-07-30 2022-06-17 香雪生命科学技术(广东)有限公司 一种识别afp抗原的t细胞受体
AU2019344871A1 (en) 2018-09-21 2021-05-20 Xlifesc, Ltd. High affinity T cell receptor for recognizing AFP antigen
CN110950949B (zh) * 2018-09-26 2022-04-05 香雪生命科学技术(广东)有限公司 一种识别ssx2抗原的t细胞受体
CA3117539A1 (en) * 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
CN111187345B (zh) 2018-11-14 2022-09-09 香雪生命科学技术(广东)有限公司 一种识别afp的高亲和力tcr
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN111662374B (zh) 2019-03-08 2023-01-24 香雪生命科学技术(广东)有限公司 一种识别afp抗原的高亲和力tcr
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
WO2021016887A1 (zh) 2019-07-30 2021-02-04 广东香雪精准医疗技术有限公司 识别ssx2抗原短肽的t细胞受体
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
CN112300268B (zh) 2019-08-02 2023-02-28 香雪生命科学技术(广东)有限公司 识别ny-eso-1抗原的高亲和力t细胞受体
CN112409474B (zh) 2019-08-23 2023-02-28 香雪生命科学技术(广东)有限公司 一种识别ssx2抗原的高亲和力tcr
CN112442119B (zh) 2019-09-05 2023-02-24 香雪生命科学技术(广东)有限公司 一种识别ssx2的高亲和力t细胞受体
JP7483865B2 (ja) * 2019-09-06 2024-05-15 イーライ リリー アンド カンパニー T細胞受容体の定常ドメインを含むタンパク質
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术(广东)有限公司 一种识别kras突变的t细胞受体及其编码序列
WO2021099906A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
CN113493505A (zh) 2020-03-20 2021-10-12 香雪生命科学技术(广东)有限公司 识别afp抗原的高亲和力tcr
CN113801217A (zh) * 2020-06-17 2021-12-17 香雪生命科学技术(广东)有限公司 一种识别hpv抗原的高亲和力t细胞受体
CN114539385A (zh) 2020-11-26 2022-05-27 香雪生命科学技术(广东)有限公司 一种识别hpv抗原的tcr
WO2022140759A2 (en) 2020-12-23 2022-06-30 Janssen Biotech, Inc. Neoantigen peptide mimics
CN115490773A (zh) * 2021-06-18 2022-12-20 香雪生命科学技术(广东)有限公司 一种针对afp抗原的高亲和力t细胞受体
CN117304301A (zh) * 2022-06-17 2023-12-29 香雪生命科学技术(广东)有限公司 一种结合ssx2抗原的tcr分子及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
RU2355703C2 (ru) * 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
CA2566363C (en) * 2004-05-19 2014-12-16 Avidex Ltd High affinity ny-eso t cell receptor
DK1758935T3 (da) 2004-05-26 2009-08-10 Immunocore Ltd Telomerase-T-cellereceptorer med höj affinitet
MX2007003910A (es) 2004-10-01 2007-06-07 Avidex Ltd Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
US20090275503A1 (en) * 2005-09-22 2009-11-05 Yeda Research And Developent Co., Ltd. At The Weizman Institute Of Science Diastereomeric peptides for modulating t cell immunity
WO2007106894A2 (en) 2006-03-15 2007-09-20 The Board Of Trustees Of The University Of Illinois Neutralizing agents for bacterial toxins
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
AU2010358291A1 (en) * 2010-07-28 2013-02-28 Immunocore Ltd T cell receptors
CN102654994B (zh) 2011-07-07 2014-08-06 京东方科技集团股份有限公司 双视显示器显示方法和双视显示器
WO2013041865A1 (en) * 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
US8524234B2 (en) * 2011-11-03 2013-09-03 Tolera Therapeutics, Inc Antibody for selective inhibition of T-cell responses
EP3015477B1 (de) 2013-06-26 2021-08-18 XLifeSc, Ltd. Hochstabiler t-zell-rezeptor und herstellungsverfahren und anwendung davon

Also Published As

Publication number Publication date
IL243365A0 (en) 2016-03-31
US20160130319A1 (en) 2016-05-12
WO2014206304A1 (zh) 2014-12-31
KR20160058085A (ko) 2016-05-24
AU2017204047A1 (en) 2017-07-06
AU2014301777B2 (en) 2017-03-30
CA2916960A1 (en) 2014-12-31
EP3015477A4 (de) 2017-01-11
CN105683215B (zh) 2021-04-23
EP3015477A1 (de) 2016-05-04
CA2916960C (en) 2022-12-06
US10654906B2 (en) 2020-05-19
CN105683215A (zh) 2016-06-15
MX2016000231A (es) 2016-10-05
NZ715815A (en) 2017-02-24
RU2645256C2 (ru) 2018-02-19
JP6549564B2 (ja) 2019-07-24
KR101904385B1 (ko) 2018-10-05
AU2017204047B2 (en) 2019-02-21
RU2016101711A (ru) 2017-07-31
EP3015477B1 (de) 2021-08-18
JP2016523268A (ja) 2016-08-08
AU2014301777A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
IL243365A0 (en) T-cells with high stability and a method for their preparation
HK1232243A1 (zh) 抗- 抗體及其用途
HK1214969A1 (zh) 抗- -β抗體及其使用
IL240166A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
HK1223544A1 (zh) 抗體製劑和方法
HK1218417A1 (zh) 螺-內酰胺 受體調節劑及其用途
IL240517A0 (en) Antibodies against b7–h4 and immunoconjugates
IL240164A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
HK1218418A1 (zh) 螺-內酰胺 受體調節劑及其用途
GB201520943D0 (en) Novel linker and preparation method thereof
IL240165A0 (en) spiro-lactam modulators of the NMDA receptor and their uses
EP2837716A4 (de) Graphenfaser und herstellungsverfahren dafür
EP2991434A4 (de) Verbindungsaufbauverfahren und -vorrichtung
IL240849A0 (en) Drug delivery devices and drug delivery method
IL243605B (en) Metallo-organic materials and a method for their preparation
HK1205214A1 (zh) 鑽土設備及鑽土方法
EP2806084A4 (de) Formungsvorrichtung und konstruktionsverfahren mit der formungsvorrichtung
SG11201602716SA (en) Injector and slip bowl system
GB201318840D0 (en) Method and device for protein preparation
IL244135A0 (en) Antibodies against fc gamma iib receptors and uses thereof
HK1218647A1 (zh) 血管加壓素- 受體激動劑
SG11201602693QA (en) Methods and intermediates for preparing macrolactams
EP2986627A4 (de) Inhibitoren des eph-a-rezeptors und verwendungen davon
GB201304271D0 (en) Composition and apparatus

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed